uploads/2018/02/Analyst-7.png

How Analysts View HCP Inc. in Fiscal 2018

By

Updated

Analyst ratings

HCP Inc.’s (HCP) performance expectations in 2018 have been reflected in its analyst ratings. Analysts gave HCP a mean price target of $26.59, implying a significant ~17.0% rise from its current level of $22.68. It has a market capitalization of ~$10.7 billion.

In February 2018, HCP received “buy” or “strong buy” ratings from four of 20 analysts. It received “hold” ratings from 15 analysts, and one analyst gave it a “sell” rating. Compared to January 2018, the number of HCP’s “strong buy” and “buy” ratings have been constant.

Article continues below advertisement

HCP’s peer ratings

Among HCP’s major alternative peers, Healthcare Trust of America (HTA) received “buy” or “strong buy” ratings from ten of 12 analysts. The remaining two analysts gave it “hold” ratings. The target price for HTA is $33.38 while the current price is $26.30.

Five of 22 analysts gave Welltower (HCN) “buy” or “strong buy” ratings, 14 analysts gave it “hold” ratings, and the remaining three gave it “sell” ratings. The target price for HCN is $67.75 from the current level of $55.79.

Two of 20 analysts gave Ventas (VTR) “buy” or “strong buy” ratings, 14 analysts gave it “hold” ratings, and the remaining four analysts gave it “underperform” ratings. The target price for VTR is $56.50, up from the current level of $51.39.

Investors looking for exposure to the healthcare real estate sector can invest in REIT ETFs. HCP holds ~1.2% in the Vanguard REIT ETF (VNQ).

Advertisement

More From Market Realist